PL3377176T3 - Sposób leczenia pacjentów otrzymujących jednocześnie rywaroksaban i werapamil - Google Patents
Sposób leczenia pacjentów otrzymujących jednocześnie rywaroksaban i werapamilInfo
- Publication number
- PL3377176T3 PL3377176T3 PL17757069T PL17757069T PL3377176T3 PL 3377176 T3 PL3377176 T3 PL 3377176T3 PL 17757069 T PL17757069 T PL 17757069T PL 17757069 T PL17757069 T PL 17757069T PL 3377176 T3 PL3377176 T3 PL 3377176T3
- Authority
- PL
- Poland
- Prior art keywords
- rivaroxaban
- coadministered
- verapamil
- treating patients
- patients
- Prior art date
Links
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 title 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 title 1
- 229960001148 rivaroxaban Drugs 0.000 title 1
- 229960001722 verapamil Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298555P | 2016-02-23 | 2016-02-23 | |
| EP17757069.4A EP3377176B1 (en) | 2016-02-23 | 2017-02-21 | Method of treating patients coadministered rivaroxaban and verapamil |
| PCT/US2017/018727 WO2017147074A1 (en) | 2016-02-23 | 2017-02-21 | METHOD OF TREATING PATIENTS COADMINISTERED A FACTOR Xa INHIBITOR AND VERAPAMIL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3377176T3 true PL3377176T3 (pl) | 2022-02-28 |
Family
ID=59630469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17757069T PL3377176T3 (pl) | 2016-02-23 | 2017-02-21 | Sposób leczenia pacjentów otrzymujących jednocześnie rywaroksaban i werapamil |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US20170239260A1 (pl) |
| EP (3) | EP3377176B1 (pl) |
| CA (1) | CA3010726A1 (pl) |
| CY (1) | CY1125307T1 (pl) |
| DK (1) | DK3377176T3 (pl) |
| ES (1) | ES2903359T3 (pl) |
| HR (1) | HRP20211946T1 (pl) |
| HU (1) | HUE056739T2 (pl) |
| LT (1) | LT3377176T (pl) |
| PL (1) | PL3377176T3 (pl) |
| PT (1) | PT3377176T (pl) |
| RS (1) | RS62797B1 (pl) |
| SI (1) | SI3377176T1 (pl) |
| SM (1) | SMT202200012T1 (pl) |
| WO (1) | WO2017147074A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10722486B2 (en) * | 2018-08-13 | 2020-07-28 | Morgandane Scientific, LLC | Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil |
| RU2743938C1 (ru) * | 2020-03-05 | 2021-03-01 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Способ профилактики тромбоза зоны реконструкции после протезирования системы воротной вены при раке поджелудочной железы |
| RU2759129C1 (ru) * | 2021-03-01 | 2021-11-09 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Способ профилактики послеоперационной тромбоэмболии легочных артерий при опухолевом тромбозе нижней полой вены |
| WO2022235779A1 (en) * | 2021-05-05 | 2022-11-10 | Angion Biomedica Corp. | Methods of administering terevalefim |
| US20250177407A1 (en) * | 2023-12-04 | 2025-06-05 | Closed Loop Medicine Ltd. | Rivaroxaban Dosing |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2278712A (en) | 1940-11-29 | 1942-04-07 | Transit Res Corp | Superresilient wheel |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR082803A1 (es) * | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p |
| UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
-
2017
- 2017-02-21 PL PL17757069T patent/PL3377176T3/pl unknown
- 2017-02-21 US US15/438,393 patent/US20170239260A1/en not_active Abandoned
- 2017-02-21 SM SM20220012T patent/SMT202200012T1/it unknown
- 2017-02-21 DK DK17757069.4T patent/DK3377176T3/da active
- 2017-02-21 SI SI201731022T patent/SI3377176T1/sl unknown
- 2017-02-21 EP EP17757069.4A patent/EP3377176B1/en active Active
- 2017-02-21 WO PCT/US2017/018727 patent/WO2017147074A1/en not_active Ceased
- 2017-02-21 PT PT177570694T patent/PT3377176T/pt unknown
- 2017-02-21 EP EP21202657.9A patent/EP3978072A1/en not_active Withdrawn
- 2017-02-21 LT LTEPPCT/US2017/018727T patent/LT3377176T/lt unknown
- 2017-02-21 RS RS20220016A patent/RS62797B1/sr unknown
- 2017-02-21 EP EP22189924.8A patent/EP4134131A1/en active Pending
- 2017-02-21 HR HRP20211946TT patent/HRP20211946T1/hr unknown
- 2017-02-21 ES ES17757069T patent/ES2903359T3/es active Active
- 2017-02-21 CA CA3010726A patent/CA3010726A1/en active Pending
- 2017-02-21 HU HUE17757069A patent/HUE056739T2/hu unknown
-
2018
- 2018-06-06 US US16/001,318 patent/US20180311256A1/en not_active Abandoned
- 2018-11-27 US US16/201,481 patent/US20190142839A1/en not_active Abandoned
- 2018-12-19 US US16/225,910 patent/US20190167693A1/en not_active Abandoned
-
2020
- 2020-12-11 US US17/119,175 patent/US20210338682A1/en not_active Abandoned
-
2022
- 2022-01-19 CY CY20221100052T patent/CY1125307T1/el unknown
-
2023
- 2023-09-01 US US18/241,389 patent/US20240252501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180311256A1 (en) | 2018-11-01 |
| SMT202200012T1 (it) | 2022-03-21 |
| LT3377176T (lt) | 2022-01-25 |
| EP3377176A4 (en) | 2019-07-31 |
| US20190167693A1 (en) | 2019-06-06 |
| US20210338682A1 (en) | 2021-11-04 |
| EP4134131A1 (en) | 2023-02-15 |
| RS62797B1 (sr) | 2022-02-28 |
| EP3377176A1 (en) | 2018-09-26 |
| ES2903359T3 (es) | 2022-04-01 |
| DK3377176T3 (da) | 2022-01-10 |
| WO2017147074A1 (en) | 2017-08-31 |
| US20190142839A1 (en) | 2019-05-16 |
| HRP20211946T1 (hr) | 2022-03-18 |
| EP3978072A1 (en) | 2022-04-06 |
| US20170239260A1 (en) | 2017-08-24 |
| CA3010726A1 (en) | 2017-08-31 |
| CY1125307T1 (el) | 2024-02-16 |
| EP3377176B1 (en) | 2021-10-20 |
| US20240252501A1 (en) | 2024-08-01 |
| HUE056739T2 (hu) | 2022-03-28 |
| PT3377176T (pt) | 2022-01-13 |
| SI3377176T1 (sl) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312607B2 (en) | Interleukin-21 Mutants and Treatment Methods | |
| IL262416A (en) | Materials and methods for the treatment of hemoglobin diseases | |
| SG10202101986UA (en) | Tetracycline compounds and methods of treatment | |
| IL262301A (en) | Liposomal preparation and methods of treatment | |
| IL257663B (en) | Oral care compositions and methods of use | |
| EP3681479A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| SG11201706767RA (en) | Materials and methods for treatment of hemoglobinopathies | |
| IL262660A (en) | Preparations for and method of treating acid-base disorders | |
| ZA201900044B (en) | Tuberculosis compositions and methods of treating or preventing tuberculosis | |
| ES3050210T3 (en) | Plasma treatment device and method of treating items | |
| IL254842A0 (en) | Therapeutic preparations and methods for use in cancer treatment | |
| IL257296B (en) | Methods of sedation and intravenous vehicle for use during critical care | |
| PL3377176T3 (pl) | Sposób leczenia pacjentów otrzymujących jednocześnie rywaroksaban i werapamil | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| PT3310946T (pt) | Método para o tratamento de superfícies de peças com geometria complexa, dispositivo porta-peças e dispositivo de tratamento | |
| GB201621737D0 (en) | Compositions and methods of treatment | |
| DK3359209T3 (en) | Compositions and methods for treatment of bone defects | |
| GB201610910D0 (en) | Composition and apparatus for treatment of chemotherapy induced alopecia | |
| GB201602802D0 (en) | Method of treatment | |
| IL267044A (en) | Photodynamic therapeutic compounds and photodynamic treatment methods | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| IL271727A (en) | Method of treatment and their dosage forms | |
| PL3268376T3 (pl) | Inhibitory enolazy i sposoby leczenia je wykorzystujące | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| IL248847A0 (en) | Dosertalin dosage and method for treating adhd |